Cornerstone Capital Inc. Acquires 107,986 Shares of OmniAb, Inc. $OABI

Cornerstone Capital Inc. acquired a new stake in OmniAb, Inc. (NASDAQ:OABI – Free Report) in the third quarter, Holdings Channel reports. The firm acquired 107,986 shares of the company’s stock, valued at approximately $536,000.

Several other large investors have also bought and sold shares of OABI. Russell Investments Group Ltd. lifted its holdings in OmniAb by 80.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 115,324 shares of the company’s stock worth $572,000 after buying an additional 51,541 shares during the period. International Assets Investment Management LLC bought a new stake in shares of OmniAb in the 3rd quarter valued at about $90,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of OmniAb in the third quarter valued at about $37,000. China Universal Asset Management Co. Ltd. increased its stake in shares of OmniAb by 15.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 26,528 shares of the company’s stock valued at $126,000 after buying an additional 3,456 shares during the period. Finally, State Street Corp raised its position in shares of OmniAb by 3.2% during the second quarter. State Street Corp now owns 2,133,549 shares of the company’s stock worth $5,249,000 after acquiring an additional 66,406 shares during the last quarter. 72.08% of the stock is owned by institutional investors.

OmniAb Stock Down 0.4%

Shares of NASDAQ OABI opened at $4.89 on Tuesday. OmniAb, Inc. has a twelve month low of $1.35 and a twelve month high of $5.45. The firm has a fifty day simple moving average of $4.75 and a 200 day simple moving average of $2.88. The company has a market capitalization of $713.26 million, a PE ratio of -14.38 and a beta of 0.60.

OmniAb (NASDAQ:OABI – Get Free Report) last released its earnings results on Friday, October 30th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $3.99 million for the quarter, compared to analyst estimates of $3.49 million. OmniAb had a negative net margin of 108.11% and a negative return on equity of 16.74%. As a group, equities analysts expect that OmniAb, Inc. will post -0.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on OABI. Leerink Partners lifted their price objective on OmniAb from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Weiss Ratings upgraded OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of OmniAb in a research report on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Check Out Our Latest Stock Analysis on OmniAb

OmniAb Company Profile

(Free Report)

OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.

Further Reading

Want to see what other hedge funds are holding OABI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OmniAb, Inc. (NASDAQ:OABI – Free Report).

Institutional Ownership by Quarter for OmniAb (NASDAQ:OABI)

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.